FDA legislation making a difference?

I'm keen to receive some other viewpoints.

Why is there the assumption that FDA legislation of mandatory breast density reporting to women would make a difference to VHT?

The reason I ask is that it seems many US states have ALREADY been mandating that they must tell women the breast density. Did those states enacting those laws affect VHT's previous sales? Did we see a big spike in activity? I guess will we ever know if we don't see breakdowns of how and where sales came from.

In Lung Screening there has not been the same grass roots "Get the patients motivated" campaign that breast cancer or breast density groups have done, nor is lung screening as big a political driver as breast, but even still I do not hear hundreds of patients jumping up and down that they MUST have their doctor use the latest lung nodule AI to check their lungs for suspicion of breast cancer, are VHT actually expecting women to scream that their doctor buys Volpara once the FDA mandates this new law? Where also is the big drive from the new US CEO, herself a cancer survivor it seems, to motivate women to lobby for Volpara?

Because I think doctors simply won't listen, they will buy what they buy based on how it affects their own practice's bottom line, not because a patient said so. I can see a health Insurance provider maybe lobbying for Volpara, but I don't get why a Doctor would be pushed by either the FDA law, or by patients. They can simply get away with using their eyes to measure density if they don't want to pay top dollar for the AI.

Anyway would love to hear more knowledgeable investors explain to me why there seems a great investment community hunger around this FDA mandate appearing on the horizon.